KAMILLA Trial Shows Practice-Changing Safety/Efficacy for HER2+ mBC
Rachel Wuerstein, MD, discusses the clinical implications of the results of the KAMILLA trial, which evaluates the benefit of trastuzumab emtansine in patients with HER2-positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment.
Rachel Wuerstein, MD, of the Unïversität Müchen, discusses the clinical implications of the results of the KAMILLA trial (NCT01702571), which evaluates the benefit of trastuzumab emtansine (T-DM1, Kadcyla) in patients with HER2-positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment.
According to Wuerstein, KAMILLA has confirmed the safety and efficacy of T-DM1 in HER2+ breast cancer. Additionally, the study did not find any new safety signals. The secondary end points of the study looked at several secondary end points of note, but no new safety signals were found.
T-DM1 isn’t just used in metastatic breast cancer, as it is moving into post-neoadjuvant treatment space. According to Wuerstein, this impacts the clinical space as it offers care providers a new treatment option for this patient population.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
FDA Grants Clearance for Phase 1 Trial of BL-M17D1 in Solid Tumors
November 11th 2024Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel antibody-drug conjugate BL-M17D1 in patients with advanced or metastatic solid tumors.
Read More
